Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

Despite the current downward trend of NVO, it is a good stock to add to one's portfolio for long-term gains due to strong ...

Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...

Spending growth for simple medications used to treat common health problems is outstripping spending growth for pricey medications used to treat complex and chronic conditions, according to a new ...

NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...

HealthDay News — Neoadjuvant semaglutide before metabolic and bariatric surgery (MBS) is not beneficial in terms of weight loss, according to a research letter published online March 5 in JAMA Surgery ...

It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...

GLP-1 drugs have revolutionised the treatment of obesity, but the very reason they are effective is also why it's vital to ...

The ‘miracle’ weight loss drug race has arrived in India with ... Danish drugmaker Novo Nordisk’s injectable semaglutide – sold under brand names Ozempic and Wegovy –may also be launched ...

MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...